Victoria Socha

DocwireNews

2021 American Transplant CongressThe United Network for Organ Sharing/Organ Procurement and Transplantation Network (UNOS/OPTN) policies 9.7 and 8.5G, enacted on August 10, 2017, were issued to establish medical criteria for simultaneous liver-kidney (SLK) transplantation and create a safety net for liver transplant recipients. One policy goal was the preservation of higher quality kidneys for <a href="https://www.docwirenews.com/latest-nephrology-news/outcomes-among-kidney-transplant-recipients-with-covid-19-2/">kidney transplant</a> candidates considered at high risk. According to J. Oveyssi and colleagues in the department of internal medicine, division of transplant nephrology, UCLA, Los Angeles, California, before the adoption of these policies, nearly half of the kidney grafts transplanted for SLK purposes had a kidney donor profile index of &lt;35%.The researchers conducted an analysis to examine the impact of the 2017 policies on kidney grafts for liver transplant candidates. Results of the analysis were reported during a virtual session at the 2021 American Transplant Congress in a presentation titled Status of Kidney Allocation in Liver-Kidney Transplant Before and After the UNOS/OPTN Policy.The researchers used the UNOS/OPTN master datafile to identify kidney transplant recipients who had previously undergone liver transplantation listed between October 1, 1987, and April 1, 2020. Groups were divided based on transplant date of January 1, 2018. Exclusion criteria included receipt of a SLK or previous kidney transplant. The analysis examined the mean and median kidney profile donor index of the kidneys transplanted and the average time to kidney transplant.During the study period, 12,216 kidney transplants following liver transplant were performed. Of those, 2033 kidney transplants were performed after January 1, 2018. Prior to January 2018, the mean (standard deviation [SD]) and median kidney donor profile index values were 37.5% ( &plusmn;26.1%) and 33.0%, respectively. After January 2018, the corresponding values were 39.1% (&plusmn;24.6%) and 37.0% (P=.008).A total of 1575 age-matched kidney after liver transplants were performed before 2018 and 260 were performed after 2018. The mean (&plusmn;SD) and median kidney donor index values before January 2018 were 55.0% (&plusmn;25.2%) and 58.0%, respectively. The values after 2018 were 56.0% (&plusmn;25%) and 59.0%, respectively (P=.6). After 2018, the average time to transplant was reduced by 27 days (P=.0001).In conclusion, the researchers said, &ldquo;The intended goals of policies 8.5G and 9.7 have been achieved, albeit modestly, since their inception. Additional follow-up is needed to ensure that these policies continue to provide a safety net for liver transplant recipients without disadvantaging at-risk kidney transplant candidates.&rdquo;Source: Oveyssi J, Hussain M, Homkrailas P, Bunnapradist S. Status of kidney allocation in liver-kidney transplants before and after the UNOS/OPTN policy. Abstract of a virtual presentation at the American Transplant Congress 2021 (abstract #29), June 5, 2021.

Dr. Sadie Dobrozsi, Evolent

Rob Dillard

Genomics Tailors Breast Cancer Care, Cuts Unneeded Chemo

Genetics & Breast Cancer

Andrew Moreno

Extending Anticoagulation is Reasonable in Children with VTE, Data Suggest

Katie Kosko

DESTINY-Breast06: T-DXd Beats Chemo in HER2-Low HR+ mBC

Breast Cancer News

Latest News

UNOS Policies 9.7 and 8.5G and Kidney Allocation in SLK Transplants

American Transplant Congress 2021

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe